Rosales Joseph, Leong Lucille A
Division of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA.
J Natl Compr Canc Netw. 2005 Jul;3(4):525-9. doi: 10.6004/jnccn.2005.0028.
The past decade has seen a significant survival improvement for patients with metastatic colorectal cancer, fueled in large part by the arrival of active novel chemotherapeutic drugs and their incorporation into combination regimens. Several randomized trials have successfully integrated oxaliplatin and irinotecan into previously existing 5-fluorouracil (5-FU)-based regimens for advanced colorectal cancer, resulting in median survivals that have risen from 9 months to almost 2 years. Even as the ideal combinations and sequences of these regimens are elucidated, targeted therapies such as recently approved bevacizumab and cetuximab have been added to treatment protocols, with favorable consequences. We review the evolution of primary chemotherapy for advanced colorectal cancer, focusing on the trials that have led to the new standard first-line treatments. We also review the data on newer targeted therapies, especially in combination with cytotoxic therapy.
在过去十年中，转移性结直肠癌患者的生存率有了显著提高，这在很大程度上得益于新型活性化疗药物的出现及其被纳入联合治疗方案。多项随机试验已成功地将奥沙利铂和伊立替康纳入先前已有的基于5-氟尿嘧啶（5-FU）的晚期结直肠癌治疗方案中，使中位生存期从9个月延长至近2年。即便这些方案的理想组合和顺序已被阐明，但诸如最近获批的贝伐单抗和西妥昔单抗等靶向治疗药物也已被添加到治疗方案中，并产生了良好的效果。我们回顾了晚期结直肠癌一线化疗的演变过程，重点关注那些促成新标准一线治疗方案的试验。我们还回顾了有关更新的靶向治疗的数据，特别是与细胞毒性疗法联合使用的数据。
